Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
Balance Sheet
9 Sheets · From 2023 to 2015Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 36.00 | 271.00 | 486.00 | 661.00 | 553.00 | 1,604.00 | 1,404.00 | 1,460.00 | 1,153.00 | |
|
Current
|
33.00 | 181.00 | 409.00 | 480.00 | 430.00 | 1,495.00 | 897.00 | 1,372.00 | 1,064.00 | |
| Cash And Equivalents | 30.00 | 39.00 | 218.00 | 77.00 | 79.00 | 507.00 | 293.00 | 218.00 | 127.00 | |
| Assets | 36.00 | 271.00 | 486.00 | 661.00 | 553.00 | 1,604.00 | 1,404.00 | 1,460.00 | 1,153.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | -8.00 | - - | - - | - - | -5.00 | - - | |
| Short Term Investments | - - | 138.00 | 187.00 | 387.00 | 335.00 | 962.00 | 571.00 | 1,118.00 | 907.00 | |
| Other Current Assets | 2.00 | 3.00 | 3.00 | 16.00 | 14.00 | 20.00 | 30.00 | 36.00 | 26.00 | |
|
Non Current
|
3.00 | 89.00 | 77.00 | 181.00 | 123.00 | 108.00 | 506.00 | 87.00 | 89.00 | |
| Property, Plant, Equipment (Net) | 3.00 | 15.00 | 14.00 | 25.00 | 80.00 | 73.00 | 69.00 | 74.00 | 71.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | 73.00 | 60.00 | 147.00 | 39.00 | 32.00 | 425.00 | 1.00 | 1.00 | |
| Other Non Current Assets | - - | - - | 1.00 | 8.00 | 2.00 | 2.00 | 11.00 | 11.00 | 16.00 | |
| Liabilities | 52.00 | 16.00 | 20.00 | 115.00 | 158.00 | 453.00 | 441.00 | 417.00 | 122.00 | |
|
Current
|
3.00 | 9.00 | 14.00 | 32.00 | 45.00 | 71.00 | 378.00 | 363.00 | 77.00 | |
| Accounts Payable | 1.00 | - - | - - | - - | 1.00 | -1.00 | 3.00 | 2.00 | 2.00 | |
| Short Term Debt | - - | - - | - - | 19.00 | 3.00 | 4.00 | 5.00 | 7.00 | 7.00 | |
| Deferred Revenue | - - | - - | - - | 11.00 | 18.00 | 23.00 | 320.00 | 290.00 | - - | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 1.00 | 7.00 | 11.00 | - - | 20.00 | 42.00 | 47.00 | 63.00 | 61.00 | |
|
Non Current
|
48.00 | 7.00 | 6.00 | 82.00 | 112.00 | 382.00 | 63.00 | 53.00 | 44.00 | |
| Long Term Debt | - - | - - | - - | - - | 68.00 | 64.00 | 58.00 | 53.00 | 44.00 | |
| Leasing Obligations | - - | - - | - - | - - | 68.00 | 64.00 | 58.00 | 60.00 | 44.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | 48.00 | 7.00 | 6.00 | 25.00 | - - | - - | - - | - - | - - | |
| Equity | -15.00 | 254.00 | 465.00 | 546.00 | 394.00 | 1,150.00 | 962.00 | 1,042.00 | 1,030.00 | |
| Stockholders' Equity | -15.00 | 254.00 | 465.00 | 546.00 | 394.00 | 1,150.00 | 962.00 | 1,042.00 | 1,030.00 | |
| Retained Earnings | -16.00 | -103.00 | -191.00 | -227.00 | -425.00 | -354.00 | -644.00 | -970.00 | -1,116.00 | |
| Common Stock | - - | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Preferred Stock | - - | - - | 486.00 | - - | - - | - - | - - | - - | - - | |
| Profit | -16.00 | -86.00 | -88.00 | -36.00 | -197.00 | 71.00 | -290.00 | -325.00 | -145.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 1.00 | 355.00 | 169.00 | 774.00 | 818.00 | 1,503.00 | 1,608.00 | 2,018.00 | 2,144.00 | |
| Loss Other Compr. Income | - - | - - | - - | - - | - - | - - | -2.00 | -6.00 | - - |